Evaluation of peptide nucleic acid array for the detection of hepatitis B virus mutations associated with antiviral resistance

Archives of Virology

Volumn 156, Issue 9, 2011, Pages 1517-1524

  Choi, Young Jin ^a   Kim, Hong Soo ^a   Lee, Sae Hwan ^a   Park, Joon Soo ^a   Nam, Hae Seon ^a   Kim, Hwi Jun ^a   Kim, Chang Jin ^a   Jeong, Dong Jun ^a   Park, Kwi Sung ^b   Baek, Kyoung Ah ^b  

^a Soonchunhyang University   (South Korea)

^b Chungcheongnam Do Institute of Health and Environment Research   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; DNA MICROARRAY; DRUG EFFECT; FEMALE; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MUTATION; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 80052262090     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-011-1019-7     Document Type: Article

References (25)

1. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP (2006) Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28: 112-125.
2. Lok A, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45: 507-539.
3. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F (2008) Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 134: 405-415.
4. Takkenberg RB, Weegink CJ, Zaaijer HL, Reesink HW (2010) New developments in antiviral therapy for chronic hepatitis B. Vox Sang 98: 481-494.
5. Seeger C, Zoulim F, Mason WS (2007) Hepadnaviruses. In: Knipe DM, Howley PM (eds) Fields virology, 5th edn. Lippincott Williams and Wilkins, Philadelphia, pp 2977-3029.
6. Ghany MG, Doo EC (2009) Antiviral resistance and hepatitis B therapy. Hepatology 49: S174-S184.
7. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L (2003) Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36: 687-696.
8. Fang J, Wichroski MJ, Levine SM, Baldick CJ, Mazzucco CE, Walsh AW, Kienzle BK, Rose RE, Pokornowski KA, Colonno RJ, Tenney DJ (2009) Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates. Antimicrob Agents Chemother 53: 2762-2772.
9. Libbrecht E, Doutreloigne J, van De Velde H, Yuen MF, Lai CL, Shapiro F, Sablon E (2007) Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. J Clin Microbiol 45: 3935-3941.
10. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C, Hepatitis B Virus Drug Resistance Working Group (2007) Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46: 254-265.
11. Jang H, Kim J, Choi JJ, Son Y, Park H (2010) Peptide nucleic acid array for detection of point mutations in hepatitis B virus associated with antiviral resistance. J Clin Microbiol 48: 3127-3131.
12. Singh RP, Oh BK, Choi JW (2010) Application of peptide nucleic acid towards development of nanobiosensor arrays. Bioelectrochemistry 79: 153-161.
13. Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, Lok AS (2006) Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 44: 1094-1097.
14. Bartholomeusz A, Locarnini S (2006) Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 78: S52-S55.
15. Soriano V, Perelson AS, Zoulim F (2008) Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother 62: 1-4.
16. Park SG, Kim Y, Park E, Ryu HM, Jung G (2003) Fidelity of hepatitis B virus polymerase. Eur J Biochem 270: 2929-2936.
17. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trépo C, Zoulim F (2000) Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32: 1078-1088.
18. Nielsen PE, Egholm M, Berg RH, Buchardt O (1991) Sequence selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254: 1497-1500.
19. Porcheddu A, Giacomelli G (2005) Peptide nucleic acids (PNAs), a chemical overview. Curr Med Chem 12: 2561-2599.
20. Ray A, Nordén B (2000) Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future. FASEB J 14: 1041-1060.
21. Pellestor F, Paulasova P, Hamamah S (2008) Peptide nucleic acids (PNAs) as diagnostic devices for genetic and cytogenetic analysis. Curr Pharm Des 14: 2439-2444.
22. Jensen KK, Orum H, Nielsen PE, Nordén B (1997) Kinetics for hybridization of peptide nucleic acids (PNA) with DNA and RNA studied with the BIAcore technique. Biochemistry 36: 5072-5077.
23. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, Toyama T, Minami M (2002) Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 37: 259-265.
24. Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Satoh J, Kobayashi M, Ikeda K, Miyakawa Y, Kumada H (2004) YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol 74: 361-366.
25. Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS (2009) Sensitivity and accuracy of an updated line probe assay (HBV DR v. 3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol 50: 42-48.